Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFEGUARD: Phase IIa open-label study of intravenous and oral F901318 plus caspofungin for antifungal prophylaxis in AML patients undergoing chemotherapy
2016-000919-33Phase 2Completed
- Sponsor
- F2G
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olorofim in invasive mycoses, sponsored by F2G. Primary endpoints: Plasma concentrations and concentration-time profile of F901318 following intravenous and oral administration and Pharmacokinetic parameters of oral F901318 at last day of administration. Started Jul 2016; status: completed.
02
Drugs
olorofim
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on 2016-000919-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000919-33.